ArticleComputational and structural biotechnology journal2021
Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease.
Article in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Pooled it
- Timing of unsaturated fat intake improves insulin sensitivity via the gut microbiota-bile acid axis: a randomized controlled trial.Nature communications · 2025Trial
- Trial
- Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina.Life (Basel, Switzerland) · 2026Article
- Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in mice.JHEP reports : innovation in hepatology · 2026Article
- Activated vitamin DScientific reports · 2025Article
- Malnutrition induces steatohepatitis by impairing hepatic lipid metabolism, mitochondrial function and the gut-liver axis.Journal of physiology and biochemistry · 2025Article
- Impact of obesity on the gut microbiome and inflammatory markers during SIV infection and antiretroviral therapy.Microbiology spectrum · 2025Article
- Transfer learning identifies bacterial signatures for cross-regional diagnosis of type 2 diabetes and enable stage-sensitive dietary fiber intervention.iMetaOmics · 2025Article
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach.Journal of advanced research · 2025Review
- Metagenomic analysis of colonic tissue and stool microbiome in patients with colorectal cancer in a South Asian population.BMC cancer · 2024Article
- Dietary L-arabinose-induced gut dysbiosis exacerbatesmSystems · 2024Article
- Gut microbiota derived from fecal microbiota transplantation enhances body weight of Mimas squabs.Animal bioscience · 2024Article
- Gut microbiome features and metabolites in non-alcoholic fatty liver disease among community-dwelling middle-aged and older adults.BMC medicine · 2024Article
- Associations between impulsivity and fecal microbiota in individuals abstaining from methamphetamine.CNS neuroscience & therapeutics · 2024Article
- Healthy diet intervention reverses the progression of NASH through gut microbiota modulation.Microbiology spectrum · 2024Article
- Gut-targeted therapies for type 2 diabetes mellitus: A review.World journal of clinical cases · 2024Review
- The influence of perilipin 5 deficiency on gut microbiome profiles in murine metabolic dysfunction-associated fatty liver disease (MAFLD) and MAFLD-hepatocellular carcinoma.Frontiers in cellular and infection microbiology · 2024Article
- Inulin-enriched Megamonas funiformis ameliorates metabolic dysfunction-associated fatty liver disease by producing propionic acid.NPJ biofilms and microbiomes · 2023Article
- Effects ofMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is closely associated with type 2 diabetes mellitus (T2D), and these two metabolic diseases demonstrate bidirectional influences. The identification of microbiome profiles that are specific to liver injury or impaired glucose metabolism may assist understanding of the role of the gut microbiota in the relationship between NAFLD and T2D. Here, we studied a biopsy-proven Asian NAFLD cohort (n = 329; 187 participants with NAFLD, 101 with NAFLD and T2D, and 41 with neither) and identified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.